Absci Investor Presentation Deck

AI-DRIVEN LEAD OPTIMIZATION Al-optimization for dual- or multi- valent biologics increases potential PRECLINICAL DEVELOPMENT Cross-species binding for improved success rates and speed G HUMAN-AG MOUSE-AG G CYNO-AG ABSCI CORPORATION 2023 ALL RIGHTS RESERVED IMMUNOLOGY Increased efficacy by simultaneous binding to multiple desired isoforms ELVE ISOFORM 1 18 ISOFORM 2 ISOFORM 3 INFECTIOUS DISEASES Broad spectrum antibodies with simultaneous binding to multiple viral variants VARIANT 1 VARIANT 2 VARIANT 3 absci. 27

View entire presentation